CLINICAL TRIALS PROFILE FOR TALIGLUCERASE ALFA
All Clinical Trials for taliglucerase alfa
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00712348 ↗ | Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase | Completed | Pfizer | Phase 3 | 2008-12-01 | This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) enzyme replacement therapy. |
| NCT00712348 ↗ | Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase | Completed | Protalix | Phase 3 | 2008-12-01 | This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) enzyme replacement therapy. |
| NCT01132690 ↗ | A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease | Completed | Pfizer | Phase 4 | 2010-08-01 | This is a multi-center, double-blind trial to assess the safety and efficacy of taliglucerase alfa in untreated subjects (2 to |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for taliglucerase alfa
Condition Name
Clinical Trial Locations for taliglucerase alfa
Trials by Country
Clinical Trial Progress for taliglucerase alfa
Clinical Trial Phase
Clinical Trial Sponsors for taliglucerase alfa
Sponsor Name
